Product
Batiraxcept
Aliases
AVB-500, AVB-S6-500
4 clinical trials
12 indications
Indication
Platinum-resistant Ovarian CancerIndication
Renal Cell CarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Fallopian Tube CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Recurrent High Grade Uterine CancerClinical trial
A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)Status: Terminated, Estimated PCD: 2023-08-04
Clinical trial
A Phase 1b/2 Study Of AVB-S6-500 In Combination With Cabozantinib, AVB-S6-500 In Combination With Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaStatus: Terminated, Estimated PCD: 2023-08-14
Clinical trial
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine CancerStatus: Not yet recruiting, Estimated PCD: 2029-01-03